Authors: Dr. Shabnam Sarshar and Dr. Harold Han
Introduction: The New Era of Personalized Cannabinoid Medicine
As hemp-derived cannabinoids step firmly into the mainstream spotlight—highlighted by growing integration into CMS systems and discussions surrounding Schedule 3 reclassification—the medical and wellness communities are coming to a profound realization: the "one-size-fits-all" approach to cannabis is obsolete. We are beginning to understand that our bodies may require personalized cannabinoid therapies down to the granular, individual level.
However, before we can tailor treatments to the individual, we must first address the most significant and consistent biological predictor of how a person will react to therapeutic cannabinoids: their biological sex. Current data conclusively show that male and female bodies differ fundamentally in how they absorb, process, and benefit from non-psychoactive cannabinoids such as Cannabidiol (CBD) and Cannabigerol (CBG).
This article is co-authored with Dr. Shabnam Sarshar, a leading expert in sex-dependent neurobiology who has dedicated her career to advancing the understanding of how plant-based cannabinoids affect women differently.
Together, we are exploring the latest peer-reviewed clinical evidence to understand the observed differences between men and women, the fascinating physiological mechanisms that drive them, and how advanced consumption methods, like water-compatible emulsions, can shape the future of equitable dosing.
Because this is a relatively new and rapidly evolving field, much of what we know about sex differences in cannabis effects still comes from animal and other preclinical studies rather than large, well‑controlled human trials. These early data are invaluable for generating hypotheses and highlighting potential mechanisms, but they do not always translate directly to real‑world human use. As a result, any sex‑specific conclusions we draw today should be viewed as provisional and subject to revision as larger and more diverse clinical studies are conducted. For readers and product developers, this means treating the current evidence as a strong signal to individualize dosing and formulations, while also recognizing that our understanding will continue to sharpen over the coming years. Most of the evidence for this pattern comes from THC‑dominant cannabis; we are extrapolating cautiously to CBD and CBG until more targeted trials are done.
Part 1: The Phenomenon – How Do Men and Women React Differently?
When men and women take the exact same oral dose of a therapeutic cannabinoid, the resulting effects, benefits, and side effects are rarely identical. Clinical studies and pharmacokinetic observations highlight several striking differences in therapeutic feedback:
-
Subjective Sensitivity and Anxiety: Women are generally more sensitive to the subjective effects of cannabinoids at lower doses. While women frequently report robust relief from anxiety, they are also statistically more prone to experiencing adverse side effects, such as nausea or increased nervousness, when taking standard cannabinoid doses compared to men (Cuttler et al., 2016).
-
Pain Management: While CBD excels at treating anxiety, men and women diverge significantly when it comes to pain treatment. Clinical research has shown that men often exhibit greater sensitivity to cannabis-elicited analgesia (pain relief) than women do (Cooper & Haney, 2016). This suggests that to achieve adequate pain relief, female patients may require specialized cannabinoid ratios or different dosing strategies than their male counterparts.
-
Blood Absorption and Accumulation: If a man and a woman take the exact same daily oral dose of CBD over several weeks, the woman will achieve a significantly higher concentration of CBD in her blood plasma (Batinić et al., 2023). Female bodies accumulate these cannabinoids more densely, meaning the therapeutic effects (and the risk of side effects) scale up much faster for women.
Part 2: The "Why" – The Physiology and Chemistry Behind the Divide
Why does a standard oral dose of CBD or CBG yield such different results? The answer lies in the distinct physiological landscapes of the male and female body.
1. Body Composition and the "Sequestration Sink": CBD and CBG are highly lipophilic, meaning they are fat-soluble and bind aggressively to adipose (fat) tissue. Because women naturally possess a higher percentage of body fat than men, the female body acts as a physiological reservoir—or a "sequestration sink"—for cannabinoids (Batinić et al., 2023). When a woman consumes oral CBD, her fat tissues absorb the compound and slowly leach it back into the bloodstream over days or weeks. This extends the duration of the drug's presence and leads to the higher cumulative blood concentrations observed in female patients (Fattore & Fratta, 2010).
2. Liver Enzymes and Metabolism: When you swallow a CBD gummy or oil, it must pass through the liver before reaching the rest of the body. The liver metabolizes cannabinoids primarily using the cytochrome P450 family of enzymes. Research indicates profound sex differences in the expression and activity of these hepatic enzymes. Females exhibit distinct metabolic processing profiles, often converting parent cannabinoids into active metabolites at a higher or different rate than males do (Narimatsu et al., 1991). This highly active enzymatic machinery fundamentally alters the drug's onset, intensity, and metabolic clearance (Forner-Piquer et al., 2024).
3. Hormonal Crosstalk: The body's natural endocannabinoid system (ECS) does not operate independently; it is deeply intertwined with sex hormones. Estradiol (estrogen) actively regulates the ECS, essentially acting as a "sensitivity multiplier." Because estrogen influences cannabinoid receptor density and the enzymes that break down our natural cannabinoids, a woman’s sensitivity to CBD and CBG fluctuates with her menstrual cycle, peaking during periods of high estrogen [Riebe et al., 2010].
4. Receptor Density and the Aging Heart: Therapeutic non-psychoactive cannabinoids interact heavily with CB2 receptors, which regulate immune responses and tissue inflammation. A fascinating sex difference emerges here as we age: in human cardiac tissue, men over the age of 50 experience a severe decline in these protective CB2 receptors. However, aging women maintain high levels of cardioprotective CB2 receptors [Piotrowska et al., 2018]. Consequently, CBD and CBG may offer uniquely potent protective cardiovascular benefits specifically for aging women.
Part 3: The Solution – Emulsions Reducing Variability
Given that women accumulate fat-soluble cannabinoids differently and metabolize them faster, relying on traditional administration routes presents a massive challenge.
When patients take traditional CBD or CBG via an oil tincture or a standard edible, the oral bioavailability is notoriously poor. Absorption is highly erratic, relying heavily on whether the patient has recently eaten a high-fat meal to help facilitate cannabinoid absorption in the small intestines. This traditional format exacerbates the variability between men and women, leading to unpredictable symptom relief.
The Emulsion Advantage: To solve this, the therapeutic cannabis industry is rapidly adopting water-compatible cannabinoid emulsions, allowing users to drink their cannabinoids.
By suspending the CBD and CBG molecules in tiny water-compatible droplets, a more effective delivery method can be achieved. Peer-reviewed pharmacokinetic studies demonstrate that these emulsified formulations drastically improve oral bioavailability and ensure a much faster onset of action compared to traditional oils (Knaub et al., 2019). More importantly, meta-regression analyses of CBD pharmacokinetics reveal emulsions can significantly lower the inter-individual variability among users (Moazen-Zadeh et al., 2023).
For patients and product designers alike, drinking water-compatible CBD or CBG emulsions represents a promising strategy to reduce some of the variability, including potential sex‑related differences. It ensures that regardless of whether the consumer is male or female, they receive a consistent, predictable, and highly absorbed therapeutic dose every single time.
Conclusion: Three Things We Now Know — And One Future We Are Building
Here is something that should genuinely surprise you: it was not until 1993 that the FDA formally required women to be included in clinical drug trials at all. For sixteen years before that, women were systematically excluded from the very studies that determined whether a drug was safe and at what dose. The result was an entire generation of pharmaceuticals calibrated on the male body and prescribed to everyone. We now know the consequences. Zolpidem, better known as Ambien, was approved in 1992 and prescribed at the same dose to men and women for over twenty years. It was only after decades of women reporting dangerous morning grogginess and impaired driving that the FDA finally cut the recommended female dose in half in 2013.
While the FDA mostly relies on a single synthetic molecule delivering one signal down one pathway, plant-based therapeutics speak in a richer language. That versatility means the sex differences described in this article are not obstacles to efficacy but are invitations to precision.
For those of us building the next generation of plant-based therapeutics, we cannot afford to wait for regulators to catch up. We must build sex-differentiated thinking into our products, our dosing protocols, and our education from the very beginning.
At the same time, the end goal is not only two categories. The end goal is the individual. Two women sharing the exact same diagnosis may still respond to CBD and CBG in ways that diverge meaningfully. The future of cannabinoid therapy is not one product for women and another for men. It is a personalized protocol, tuned to the individual, that evolves as the individual changes.
This is the frontier of medicine.